Genmab — Januar 2017
-
Det er en cyklisk symbiose mellem AB og danske/skandinaviske banker. Når den ene casher ind køber den anden og når den anden genkøber casher den første ind = alle er glade undtagen private aktører der føler sig manipuleret med, men det er omsætningen nok for høj til. Mange investeringsforeninger har Genmab da de er repræsenteret i forskellige elite-indeks og derfor er det bare et salg af de "samme" aktier gang på gang med forskellige motiver, men generelt er der tale om en processuel strukturel
-
-
Direkte+ indirekte kostnader MS Patienter idag 8.525-54.240 Us dollars År. Der findes 400000 amerikaner med MS I verden 2.500.000 patienter med Multiple Scleros. Azerra har vist 90 % reduktion av nye läsioner i hjärnan i fas 2 forsök Nu körer fas 3 Genmab kan her OGSÅ HA EN BLOCKBURSTER
-
My guess is that we'll be seeing more uptrend in Genmab driven by the Actelion deal. When the deal was first announced smart money moved out of EU biotech into Actelion (would also explain the fact that Genmab almost didn’t move after all the fantastic data shared on ASH). Now that the deal is announced smart money is slowly moving out of Actelion and moving back into EU biotech. After completion Genmab is the no.1 EU biotech, it wouldn’t surprise me if we’re going to see big inflow in Genmab
-
the coming months, especially after all Actelion stakeholders receiver their funds. Until now only +/- 5% off shares have been traded hands at the 272-276 CHF level.
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind